- Home
- ALGS vs NRSN Comparison
ALGS vs NRSN Comparison
Compare ALGS & NRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALGS
- NRSN
- Stock Information
- Founded
- ALGS 2018
- NRSN 2017
- Country
- ALGS United States
- NRSN Israel
- Employees
- ALGS N/A
- NRSN N/A
- Industry
- ALGS Biotechnology: Pharmaceutical Preparations
- NRSN Biotechnology: Pharmaceutical Preparations
- Sector
- ALGS Health Care
- NRSN Health Care
- Exchange
- ALGS Nasdaq
- NRSN Nasdaq
- Market Cap
- ALGS 36.0M
- NRSN 37.9M
- IPO Year
- ALGS 2020
- NRSN 2021
- Fundamental
- Price
- ALGS $7.20
- NRSN $1.79
- Analyst Decision
- ALGS Strong Buy
- NRSN Buy
- Analyst Count
- ALGS 1
- NRSN 2
- Target Price
- ALGS $70.00
- NRSN $14.00
- AVG Volume (30 Days)
- ALGS 156.2K
- NRSN 297.9K
- Earning Date
- ALGS 08-05-2025
- NRSN 06-23-2025
- Dividend Yield
- ALGS N/A
- NRSN N/A
- EPS Growth
- ALGS N/A
- NRSN N/A
- EPS
- ALGS N/A
- NRSN N/A
- Revenue
- ALGS $3,270,000.00
- NRSN N/A
- Revenue This Year
- ALGS N/A
- NRSN N/A
- Revenue Next Year
- ALGS N/A
- NRSN N/A
- P/E Ratio
- ALGS N/A
- NRSN N/A
- Revenue Growth
- ALGS N/A
- NRSN N/A
- 52 Week Low
- ALGS $3.76
- NRSN $0.51
- 52 Week High
- ALGS $46.80
- NRSN $1.80
- Technical
- Relative Strength Index (RSI)
- ALGS 62.71
- NRSN 73.77
- Support Level
- ALGS $5.47
- NRSN $1.65
- Resistance Level
- ALGS $6.12
- NRSN $1.77
- Average True Range (ATR)
- ALGS 0.59
- NRSN 0.14
- MACD
- ALGS 0.21
- NRSN 0.02
- Stochastic Oscillator
- ALGS 88.92
- NRSN 100.00
About ALGS Aligos Therapeutics Inc.
Aligos Therapeutics Inc is a clinical stage biopharmaceutical company. It is engaged in developing novel therapeutics to address unmet medical needs in viral and liver diseases, including chronic hepatitis B and coronaviruses, and therapeutics for nonalcoholic steatohepatitis (NASH). The company's pipeline includes ALG-010133, ALG-000184, ALG-020572 and ALG-055009, among others.
About NRSN NeuroSense Therapeutics Ltd.
NeuroSense Therapeutics Ltd is a clinical-stage biotechnology company focused on discovering and developing treatments for patients suffering from debilitating neurodegenerative diseases. These diseases include Amyotrophic Lateral Sclerosis, or ALS, Alzheimer's disease, and Parkinson's disease, among others. Its product candidate, PrimeC, is a novel extended-release or ER, oral formulation of a fixed dose combination of two generic FDA-approved drugs, ciprofloxacin and celecoxib, combined in a specific ratio.